In a significant development for ANI Pharmaceuticals, Inc. the leading pharmaceutical company has announced the successful closing of its offering of $316,250,000 aggregate principal amount of 2.25% convertible senior notes due 2029. This private offering, which saw substantial demand from qualified institutional buyers, highlights the companyns position as a key player in the industry. ANI Pharmaceuticals, Inc. opted to upsize the initial offering to $275,000,000 due to overwhelming investor interest, and the initial purchasers exercised their option to purchase an additional $41,250,000 aggregate principal amount of the notes. The notes, which were issued under the supervision of U.S. Bank Trust Company, National Association as trustee, are governed by an indenture agreement dated August 13, 2024.